Inhibition of interleukin‐6 synthesis in an animal model of septic shock by anti‐C5a monoclonal antibodies
- 1 May 1996
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 26 (5), 1103-1109
- https://doi.org/10.1002/eji.1830260522
Abstract
The complement activation fragment C5a was recently shown to induce interleukin (IL)‐6 synthesis by peripheral blood mononuclear cells. To understand better the role of C5a in cytokine regulation in vivo, we investigated the effects of complement depletion by cobra venom factor (CVF) or of anti‐C5a monoclonal antibodies (mAb) on IL‐6 generation in an animal model of septic shock. Complement‐depleted pigs which were subsequently challenged with Escherichia coli generated significantly (p < 0.05) less IL‐6 during the 6‐h observation period than complement‐sufficient controls. To address specifically the role of C5a in IL‐6 regulation, we produced a C5a(57–74) peptide‐specific mAb (T13/9) which neutralizes the bioactivity of porcine C5a. The mAb T13/9 does not crossreact with the precursor protein C5. The pretreatment of pigs with anti‐C5a mAb T13/9 prior to the induction of sepsis resulted in a decrease of over 75 % in serum IL‐6 bioactivity compared to control animals (p < 0.0001). These results indicate a role for C5a in the modulation of IL‐6 synthesis in Gram‐negative bacteremia.This publication has 25 references indexed in Scilit:
- Gene expression of interleukin-1β during hemodialysisKidney International, 1993
- Limited involvement of interleukin‐6 in the pathogenesis of lethal septic shock as revealed by the effect of monoclonal antibodies against interleukin‐6 or its receptor in various murine modelsEuropean Journal of Immunology, 1992
- Human recombinant C5a enhances lipopolysaccharide‐induced synthesis of interleukin‐6 by human monocytesEuropean Journal of Clinical Investigation, 1992
- Cytokines and their interactions with other inflammatory mediators in the pathogenesis of sepsis and septic shockEuropean Journal of Clinical Investigation, 1991
- C5a-mediated release of interleukin 6 by human monocytesClinical Immunology and Immunopathology, 1990
- Recombinant C5a enhances interleukin 1 and tumor necrosis factor release by lipopolysaccharide‐stimulated monocytes and macrophagesEuropean Journal of Immunology, 1990
- Production of hybridoma growth factor by human monocytesEuropean Journal of Immunology, 1987
- Evaluation of low dose anaphylatoxic peptides in the pathogenesis of the adult respiratory distress syndrome (ARDS). Monitoring of early C5a effects in a guinea-pig in vivo model after i.v. applicationEuropean Journal of Clinical Investigation, 1986
- Effects of anti-C5a antibodies on the adult respiratory distress syndrome in septic primates.Journal of Clinical Investigation, 1986
- Cobra venom factor: Improved method for purification and biochemical characterizationJournal of Immunological Methods, 1984